JP2023519491A - 癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物 - Google Patents

癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物 Download PDF

Info

Publication number
JP2023519491A
JP2023519491A JP2022549886A JP2022549886A JP2023519491A JP 2023519491 A JP2023519491 A JP 2023519491A JP 2022549886 A JP2022549886 A JP 2022549886A JP 2022549886 A JP2022549886 A JP 2022549886A JP 2023519491 A JP2023519491 A JP 2023519491A
Authority
JP
Japan
Prior art keywords
cxcl8
inhibitor
radiotherapy
use according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519491A5 (https=
Inventor
アレグレッティ マルチェロ
ルフィニ ピエラデルチ
Original Assignee
ドンペ ファーマスーチシ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドンペ ファーマスーチシ ソシエタ ペル アチオニ filed Critical ドンペ ファーマスーチシ ソシエタ ペル アチオニ
Publication of JP2023519491A publication Critical patent/JP2023519491A/ja
Publication of JP2023519491A5 publication Critical patent/JP2023519491A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022549886A 2020-02-21 2021-02-19 癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物 Pending JP2023519491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158787.0 2020-02-21
EP20158787.0A EP3868369A1 (en) 2020-02-21 2020-02-21 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
PCT/EP2021/054231 WO2021165510A1 (en) 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Publications (2)

Publication Number Publication Date
JP2023519491A true JP2023519491A (ja) 2023-05-11
JP2023519491A5 JP2023519491A5 (https=) 2023-12-07

Family

ID=69723868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549886A Pending JP2023519491A (ja) 2020-02-21 2021-02-19 癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物

Country Status (7)

Country Link
US (1) US20230090111A1 (https=)
EP (2) EP3868369A1 (https=)
JP (1) JP2023519491A (https=)
AU (1) AU2021222360A1 (https=)
CA (1) CA3166653A1 (https=)
IL (1) IL294722A (https=)
WO (1) WO2021165510A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHASE DOYLE: "DEXAMETHASONE PLUS EXERCISE MAY REDUCE FATIGUE IN PATIENTS WITH ADVANCED CANCER - THE ASCO POST", [ONLINE], JPN5023005349, 25 November 2019 (2019-11-25), pages 1 - 4, ISSN: 0005619150 *
J OF ALLERGY CLIN IMMUNOL, vol. 130, no. 4, JPN6024052175, 2012, pages 877 - 885, ISSN: 0005619154 *
J OF CLINICAL ONCOLOGY, vol. VOL:31,NR:25, JPN5023005352, 2013, pages 3076 - 3082, ISSN: 0005619153 *
J OF CLINICAL ONCOLOGY, vol. VOL:37, NR:31_SUPPL, JPN5023005350, 2019, pages 1 - 3, ISSN: 0005619151 *
J OF PAIN AND SYMPTOM MANAGEMENT, vol. VOL:52,NR:1, JPN5023005351, 2016, pages 64 - 72, ISSN: 0005619152 *
SUPPORTIVE CARE IN CANCER, vol. Vol. 30, Supp. Supplement 1, JPN6024052174, 23 June 2022 (2022-06-23), pages 45 - 46, ISSN: 0005492085 *

Also Published As

Publication number Publication date
WO2021165510A1 (en) 2021-08-26
AU2021222360A1 (en) 2022-09-01
IL294722A (en) 2022-09-01
US20230090111A1 (en) 2023-03-23
CA3166653A1 (en) 2021-08-26
EP4106739A1 (en) 2022-12-28
EP3868369A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
KR20140069340A (ko) 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
JP2024533423A (ja) 薬学的組成物およびその使用
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
JP7590351B2 (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
CA3186786A1 (en) Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
AU2022397653A1 (en) Pharmaceutical composition and use thereof
EP3967310B1 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
US20230038138A1 (en) Combination therapy for treating cancer
RU2832833C1 (ru) Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком
JP2023519491A (ja) 癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物
JP2003277265A (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
CN119894514A (zh) 药物组合物及其用途
US10857113B2 (en) Bezafibrate for the treatment of cancer
JP5830983B2 (ja) 抗癌剤の副作用軽減剤
US20250319068A1 (en) Treatment of diseases via administration of buntanetap and an antihypertensive agent
US20240350497A1 (en) Combination therapy for the treatment of pan-kras mutated cancers
JP2009511535A (ja) ５−（２−クロロフェニル）−１，２−ジヒドロ−７−フルオロ−８−メトキシ−３−メチル−ピラゾロ［３，４−ｂ］［１，４］ベンゾジアゼピン
WO2024023766A1 (en) P13k inhibitor combination therapy
HK40067831A (en) Methods of treating cancer using prmt5 inhibitors
WO2025248485A1 (en) Pharmaceutical compositions and methods of use thereof
US9353119B2 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
CN121926940A (zh) 布鲁顿酪氨酸激酶抑制剂的用途
TW202345848A (zh) 使用突變idh抑制劑之組合療法
US20060258736A1 (en) Dosing regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617